ROTHBLATT MARTINE A sold $4.9M of UTHR (indirect holdings)
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $518.74 ($502.29–$524.59, $4.93M total) across 16 trades on 2026-08-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new information is the specific sale execution details (shares, price range, total value) and the confirmation that it was pre-arranged.
Market read
This provides a fresh, timestamped insider-sale datapoint, but it does not introduce new fundamentals or guidance.
What to watch
Traders may also consider whether the sale size is large relative to prior insider activity and whether other insiders filed concurrent transactions, but those details are not provided here.
Background
The article is a SEC Form 4 insider transaction disclosure for United Therapeutics, reported by its Chairperson and CEO via an indirect holding sale under a Rule 10b5-1 plan.
Ticker impact
United Therapeutics CEO sold $4.93M of UTHR via a Rule 10b5-1 plan, with 9,500 shares sold across 16 trades on 2026-08-05.
Likely modest, short-lived sentiment impact at most; no direct fundamental change is disclosed.
The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, and the article provides no new operational, regulatory, or financial catalyst beyond the sale details.
Market effects
Limited spillover to biotech/large-cap pharma peers because the disclosure is company-specific and does not cite sector-wide developments.
No clear regional market linkage beyond US large-cap sentiment.
Low global relevance; this is a routine insider transaction disclosure.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations, so any price reaction could be overdone.
Key entities
- issuerUNITED THERAPEUTICS Corp
US-listed company whose CEO reported an insider sale under a Rule 10b5-1 plan.
- insiderROTHBLATT MARTINE A
Chairperson and CEO who sold 9,500 shares indirectly via multiple trades.
